Online Enquiry
Subscribe
Log in / New User
Retrieve Password
此页面上的内容需要较新版本的 Adobe Flash Player。
切换导航
Home
Pharma China Web Edition
Pharma China Archives
Online Databases
Subscription/Download
Event Calendar
China Pharma Providers
About Us
Location:
Home
> Pharma China Web Edition
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Feature articles
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
News in Focus
Editor's Picks
Full Text
Title
Subscribe to Pharma China
Online Enquiry
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
News in Focus
Editor's Picks
ONLINE ENQUIRY
WiCON International Group
Bellevue, WA 98007, USA
info@pharmachinaonline.com
WiCON International Co. Ltd.
Osaka, Japan
info@pharmachinaonline.com
Industry News
4/29/2025
AstraZeneca's China Business Recovers in Q1 2025 Amid Easing Regulator...
4/29/2025
China Orders Drugmakers, Hospitals to Study US Import Replacements
4/29/2025
ConjugateBio Secures Exclusive Option for Escugen's EZWi-Fit® Platfor...
4/29/2025
Europe Emerges as Key Partner for China Pharma Deals Amid US Market Sh...
4/29/2025
AmCham China Reports Chinese Tariff Exemptions for Some Pharma Firms A...
4/29/2025
InnoCare's Orelabrutinib Receives NMPA Approval as First-Line Therapy ...
4/29/2025
Hengrui Secures Approval for Hong Kong IPO
4/29/2025
JW and Juno Forge sLVV Licensing Agreement to Advance Cell Therapy Man...
4/29/2025
Ribo Life Science Files for IPO on HKSE, Backed by CICC and Citi
4/29/2025
PegBio Poised for IPO on Hong Kong Stock Exchange Following Successful...
4/29/2025
3SBio Advances Novel MUC17-Targeting Therapy SSS59 into Global Phase 1...
4/29/2025
DualityBio and AstraZeneca Unite to Investigate Novel Lung Cancer Comb...
4/29/2025
Qyuns Sets Up Newco for Global Rights to Its Novel Long-Acting BsAb QX...
4/25/2025
China's Innovative Drug Licensing Deals Soar, Big Pharma Leads the Buy...
4/25/2025
China's Fast-Track Drug Approvals Accelerating Access to Novel Therapi...
4/25/2025
AstraZeneca China Announces Major Reorganization to Bolster Biopharma ...
4/25/2025
JIBP Aims for Hong Kong IPO amid Biopharma Market Revival
4/24/2025
LTZ Thera Secures $40M in Oversubscribed Series A+ to Advance FIC Im...
4/24/2025
Merck's Gardasil Sales Plunge Amid China Market Turbulence
4/24/2025
Bayer Pharma Accelerates Growth in China with Breakthru Therapies and ...
4/24/2025
Ascletis Challenges Lilly, Novo With Promising Oral GLP-1 Data
4/23/2025
Global Pharma Feels 'Sense of Urgency' to De-Risk from China Amid Risi...
4/23/2025
China Accelerates Development of Multivalent Vaccines and Digital Immu...
4/22/2025
Carbogen Amcis Secures Chinese Drug Manufacturing License
4/22/2025
Fujifilm Capitalizes on U.S.-China Tensions with $3B Biopharma Deal
4/22/2025
Fosun Boosts Stake in Henlius After Failed Privatization Attempt
4/22/2025
GemPharmatech Establishes San Diego Facility Amid U.S. Crackdown on Ch...
4/22/2025
VelaVigo Announces Second Out-Licensing Deal for a FIC BsAb
4/22/2025
Sanofi and Cathay Capital Launch $275M Fund to Boost Chinese Drug Comm...
4/19/2025
Haleon Achieves Full Ownership of Tianjin SmithKline JV
Page:
1
/
21
Total number of articles:
630
:
[First]
[<<]
[1]
[2]
[3]
[4]
[5]
[>>]
[End]
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
FEATURE ARTICLES
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
News in Focus
Editor's Picks
GENERAL INFORMATION
TERMS & CONDITIONS OF USE
Download Info
Contact Us
Site map
|
Contact Us
|
Links
© Wicon International Group
×
Join the mailing list
We will e-mail you the most critical news and developments about China's healthcare sector, in real time and absolutely free.
name:
e-mail:
company:
submit